SUNNYVALE, Calif.–(BUSINESS
WIRE)–IntraOp Medical Corporation today announced that Helios Berlin Buch became the fourth German hospital and
the nineteenth European hospital to purchase a Mobetron for Intra-Operative
Electron Radiation Therapy (IOERT).
“IOERT is becoming the gold standard in the successful
treatment of cancer,” says Ernesto G. Lanzotti, Director of MD51 Germany GmbH,
IntraOp Medical European distributor. “The clinical data showing the
effectiveness of IOERT, compared to conventional treatment is very convincing.
German hospitals are all looking to provide their patients the best cancer
treatment possible-and that is IOERT. We are very proud to start cooperating
with helios-kliniken.de because we understand the importance
from both a treatment and medical science aspect and the potential they will be
able to bring in terms of future treatments. With our existing German customers
already operating in Germany
at a level of excellence, we are sure IOERT will have a big increase already in
the next few months.”
Helios Berlin Buch in the city of Berlin
is the reference site among most important treatment centers in Germany, very
famous for its Breast Cancer unit and for the state of the art in Medical
Technology.
“We are very excited to add Helios Group to a growing list
of world class cancer centers using the Mobetron. IOERT for breast cancer is
becoming very prevalent throughout Europe,”
said John Powers, President and CEO of IntraOp Medical. IntraOps Mobetron is a mobile, self-shielded, device that delivers
radiation directly to the tumor site during cancer surgery protecting surrounding
body structures from radiation. This procedure is called IORT. The Mobetron
uses electron radiation, IOERT, which is the fastest, safest, most versatile,
and precise way to deliver radiation therapy. The Mobetron delivers
concentrated electron radiation directly to the exposed tumor bed to an exact
depth during cancer surgery.
About IntraOp
IntraOp Medical Corporation provides innovative technology solutions for the
treatment and eradication of cancer. Founded in 1993, IntraOp is committed to
providing the tools doctors need to administer IOERT safely and effectively for
all cancer patients. The Mobetron is the first IOERT device designed for use in
existing operating rooms or office settings and has been used to treat over 20
different cancer indications. Mobetron benefits include: increased survival
rates, better local tumor control, shorter treatment cycles, and fewer side
effects. Leading hospitals and clinics in North America, Europe, and Asia, use the Mobetron as a vital part of their comprehensive
cancer program.
Posted by Sean Fenske, Editor-in-Chief, MDT
